Sclerostin monoclonal antibodies on bone metabolism and fracture healing

Bibliography

• Winkler DG, Sutherland MK, Geoghegan JC, Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003;22:6267-76
   PubMed Web of Science ®Google Scholar
• Lin C, Jiang X, Dai Z, Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009;24:1651-61
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Y, Kang H, Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280:19883-7
   PubMed Web of Science ®Google Scholar
• Ott SM. Sclerostin and Wnt signaling–the pathway to bone strength. J Clin Endocrinol Metab 2005;90:6741-3
   PubMed Web of Science ®Google Scholar
• Glass DA II, Bialek P, Ahn JD, Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751-64
   PubMed Web of Science ®Google Scholar
• Wijenayaka AR, Kogawa M, Lim HP, Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 2011;6:e25900
   PubMed Web of Science ®Google Scholar
• Wijenayaka A, Kogawa M, Findlay D, Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. ASBMR Annual Meeting Abstracts; 2011
   Google Scholar
• Li X, Ominsky MS, Niu QT, Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008;23:860-9
   PubMed Web of Science ®Google Scholar
• Li C, Ominsky MS, Tan HL, Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone 2011;49:1178-85
   PubMed Web of Science ®Google Scholar
• Li X, Ominsky MS, Warmington KS, Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24:578-88
   PubMed Web of Science ®Google Scholar
• Marenzana M, Greenslade K, Eddleston A, Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 2011;63:2385-95
   PubMed Web of Science ®Google Scholar
• Eddleston A, Marenzana M, Moore AR, A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 2009;24:1662-71
   PubMed Web of Science ®Google Scholar
• Ominsky MS, Vlasseros F, Jolette J, Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25:948-59
   PubMed Web of Science ®Google Scholar
• Li X, Warmington KS, Niu QT, Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010;25:2647-56
   PubMed Web of Science ®Google Scholar
• Padhi D, Jang G, Stouch B, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26
   PubMed Web of Science ®Google Scholar
• Agholme F, Li X, Isaksson H, Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010;25:2412-18
   PubMed Web of Science ®Google Scholar
• Agholme F, Isaksson H, Li X, Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats. Acta Orthop 2011;82:628-32
   PubMedGoogle Scholar
• Alkhiary YM, Gerstenfeld LC, Krall E, Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 2005;87:731-41
   PubMed Web of Science ®Google Scholar
• Tsiridis E, Morgan EF, Bancroft JM, Effects of OP-1 and PTH in a new experimental model for the study of metaphyseal bone healing. J Orthop Res 2007;25:1193-203
   PubMed Web of Science ®Google Scholar
• Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radial fractures. Acta Orthop 2010;81:234-6
   PubMed Web of Science ®Google Scholar
• Aspenberg P, Genant HK, Johansson T, Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010;25:404-14
   PubMed Web of Science ®Google Scholar
• Ominsky MS, Li C, Li X, Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 2011;26:1012-21
   PubMed Web of Science ®Google Scholar
• Brunkow ME, Gardner JC, Van Ness J, Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001;68:577-89
   PubMed Web of Science ®Google Scholar
• Little RD, Carulli JP, Del Mastro RG, A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002;70:11-19
   PubMed Web of Science ®Google Scholar
• Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet 2003;63:192-7
   PubMed Web of Science ®Google Scholar
• Van Bezooijen RL, Ten Dijke P, Papapoulos SE, SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005;16:319-27
   PubMed Web of Science ®Google Scholar
• Liu M, Kurimoto P, Niu Q-T, Effect of estrogen deficiency in sclerostin knockout mice. ASBMR Annual Meeting Abstracts; 2011
   Google Scholar
• Robling AG, Niziolek PJ, Baldridge LA, Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008;283:5866-75
   PubMed Web of Science ®Google Scholar
• Morse A, McDonald MM, Kramer I, Bone volume is not altered with unloading in the homozygous sclerostin knockout mouse. ORS Annual Meeting; 2012
   Google Scholar
• Sarahrudi K, Thomas A, Albrecht C, Strongly enhanced levels of sclerostin during human fracture healing. J Orthop Res 2012. [Epub ahead of print]
   Web of Science ®Google Scholar
• Li X, Warmington S, Xia XC, Sclerostin antibody prevents bone loss and increases bone formation in female rats with high turnover due to ovariectomy. ASBMR Annual Meeting Abstracts; 2011
   Google Scholar
• Li X, Warmington KS, Niu Q-T, Sclerostin Inhibition by Monoclonal Antibody Reversed Trabecular and Cortical Bone Loss in Orchiectomized Rats with Established Osteopenia. ASBMR Annual Meeting Abstracts; 2010
   Google Scholar
• Stolina M, Dwyer D, Niu Q-T, Treatment With a Sclerostin Antibody Increased Osteoblast-derived Markers of Bone Formation and Decreased Osteoclast-related Markers of Bone Resortion in Ovariectomised Rats. ASBMR Annual Meeting Abstracts; 2010
   Google Scholar
• Lewiecki EM. Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin Biol Ther 2011;11:117-27
   PubMed Web of Science ®Google Scholar
• Hirano T, Burr DB, Turner CH, Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999;14:536-45
   PubMed Web of Science ®Google Scholar
• Burr DB, Hirano T, Turner CH, Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001;16:157-65
   PubMed Web of Science ®Google Scholar
• Kirmani S, Amin S, McCready LK, Sclerostin levels during growth in children. Osteoporos Int 2012;23:1123-30
   PubMed Web of Science ®Google Scholar
• Tian X, Jee WS, Li X, Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 2011;48:197-201
   PubMed Web of Science ®Google Scholar
• Li X, Ominsky MS, Warmington KS, Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology 2011;152:3312-22
   PubMed Web of Science ®Google Scholar
• Phase 2 Study of AMG 785 in Postmenopausal Women With Low Bone Mineral Density. Available from: http://clinicaltrials.gov/ct2/show/NCT00896532
   Google Scholar
• A Study to Evaluate the Effect of AMG 785 on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass. Available from: http://clinicaltrials.gov/ct2/show/NCT00950950
   Google Scholar
• Virdi A, Sena K, Liu M, Enhanced Peri-Implant Bone Formation and Fixation by Sclerostin Antibody in a Rat Ovariectomy Model. ASBMR Annual Meeting Abstracts; 2011
   Google Scholar
• Sena K, Liu M, Ke HZ, Sclerostin Antibody Increases Peri-implant Bone Formation in Sham-ovariectomised and Ovariectomised Rats. ASBMR Annual Meeting Abstracts; 2011
   Google Scholar
• Virdi A, Sena K, Maletich J, Bone implant fixation augmentation with anti-sclerostin antibody treatment in rats. J Bone Miner Res 2009;24:S375
   Google Scholar
• Irish JM, Virdi AS, Sena K, Sclerostin Antibody Enhances Bone-Implant Contact by Increasing Bone Formation and Inhibiting Bone Resorption. ORS Annual Meeting; 2012
   Google Scholar
• Spatz J, Ellman R, Cloutier AM, Treatment with Sclerostin Antibody Increases Bone Mass and Strength During Hindlimb Unloading. ASBMR Annual Meeting abstracts; 2011
   Google Scholar
• Ke HZ, Xiang JJ, Li X, Inhibition of sclerostin by systemic treatment with a sclerostin monoclonal antibody enhances fracture healing in mice and rats. Trans Orthop Res Soc 2009;34:221
   Google Scholar
• He YX, Liu Z, Man CW, Inhibition of Sclerostin by Monoclonal Antibody Enhances Bone Healing in rat Osteotomy Model. ORS Annual Meeting; 2012
   Google Scholar
• Virk M, Saquib S, Farhang A, Influence of sclerostin antibody on bone repair in a rat femoral defect model. Trans Orthop Res Soc 2009;34:607
   Google Scholar
• Alaee F, Tang A, Ominsky M, Sclerostin Antibody Enhances Bone Repair in a Rat Femoral Defect Model. ASBMR Annual Meeting Abstracts; 2011
   Google Scholar
• He Y, Liu Z, Tang T, Inhibition of Sclerostin by Monoclonal Antibody Enhances Bone Healing in a Rat Osteotomy Model. ASBMR Annual Meeting Abstracts; 2011. [Epub ahead of print]
   Google Scholar
• McDonald MM, Morse A, Mikulec K, Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res 2012
   PubMed Web of Science ®Google Scholar
• Study of AMG 785 in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing. Available from: http://clinicaltrials.gov/ct2/show/NCT00907296
   Google Scholar
• Study To Assess Fracture Healing With Sclerostin Antibody. Available from: http://clinicaltrials.gov/ct2/show/NCT01081678
   Google Scholar
• Tsiridis E, Gamie Z, Conaghan PG, Biological options to enhance periprosthetic bone mass. Injury 2007;38:704-13
   PubMed Web of Science ®Google Scholar
• Black DM, Bilezikian JP, Ensrud KE, One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-65
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15
   PubMed Web of Science ®Google Scholar
• Halleux C, Hu S, Prassler J, Infrequent Co-treatment and Sequential Treatment of Anti-sclerostin Antibody with Zoledronic Acid Restores and Maintains Bone Mass in Murine Osteoporosis Models. Proceedings of the ASBMR Annual Meeting; 2009
   Google Scholar
• Court-Brown CM, Aitken S, Hamilton TW, Nonoperative fracture treatment in the modern era. J Trauma 2010;69:699-707
   PubMed Web of Science ®Google Scholar
• Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-18
   PubMed Web of Science ®Google Scholar
• Zuckerman JD. Hip fracture. N Engl J Med 1996;334:1519-25
   PubMed Web of Science ®Google Scholar
• Tsialogiannis E, Polyzois I, Oak Tang Q, Targeting bone morphogenetic protein antagonists: in vitro and in vivo evidence of their role in bone metabolism. Expert Opin Ther Targets 2009;13:123-37
   PubMed Web of Science ®Google Scholar
• Shaffer A, Shonuga OA, Hirsch B, Sclerostin Antibody Enhances Spine Fusion in a Rat Posterolateral Transverse Process Fusion Model: Preliminary Results. ASBMR Annual Meeting Abstracts; 2011
   Google Scholar
• Shaffer AD, Shonuga OA, Hirsch BP, Anti-Sclerostin (Scl-Ab) Increases Bone Mass and Fusion Volume in a Rat Posterolateral Spinal Fusion Model. ORS Annual Meeting; 2012
   Google Scholar
• Johansson HR, Skripitz R, Aspenberg P. Bisphosphonates can block the deterioration in implant fixation after withdrawal of intermittent doses of parathyroid hormone. J Bone Joint Surg Br 2008;90:400-4
   PubMed Web of Science ®Google Scholar
• Skripitz R, Aspenberg P. Implant fixation enhanced by intermittent treatment with parathyroid hormone. J Bone Joint Surg Br 2001;83:437-40
   PubMed Web of Science ®Google Scholar
• Zati A, Sarti D, Malaguti MC, Teriparatide in the treatment of a loose hip prosthesis. J Rheumatol 2011;38:778-80
   PubMed Web of Science ®Google Scholar
• Oteo-Alvaro A, Matas JA, Alonso-Farto JC. Teriparatide (rh [1-34] PTH) improved osteointegration of a hemiarthroplasty with signs of aseptic loosening. Orthopedics 2011;34:e574-7
   Google Scholar
• Kansara M, Tsang M, Kodjabachian L, Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009;119:837-51
   PubMed Web of Science ®Google Scholar
• Niu Q-T, Li X, Ke HZ. Increased Subchondral Bone Mass with No Histological Changes in Articular Cartilage in Sclerostin Knockout Mice and Rats Treated with Sclerostin Monoclonal Antibody. ORS Annual Meeting; 2012
   Google Scholar